Terms: = Ovarian cancer AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Treatment
52 results:
1. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract] [Full Text] [Related]
2. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.
Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
[TBL] [Abstract] [Full Text] [Related]
3. Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial ovarian cancer.
Wang CW; Lee YC; Lin YJ; Firdi NP; Muzakky H; Liu TC; Lai PJ; Wang CH; Wang YC; Yu MH; Wu CH; Chao TK
Lab Invest; 2023 Nov; 103(11):100247. PubMed ID: 37741509
[TBL] [Abstract] [Full Text] [Related]
4. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
5. DNA Repair Pathway in ovarian cancer Patients Treated with HIPEC.
Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
[TBL] [Abstract] [Full Text] [Related]
6. Germline drivers of gynecologic carcinosarcomas.
Sia TY; Gordhandas SB; Birsoy O; Kemel Y; Maio A; Salo-Mullen E; Sheehan M; Hensley ML; Rubinstein M; Makker V; Grisham RN; O'Cearbhaill RE; Roche KL; Mueller JJ; Leitao MM; Sonoda Y; Chi DS; Abu-Rustum NR; Berger MF; Ellenson LH; Latham A; Stadler Z; Offit K; Aghajanian C; Weigelt B; Mandelker D; Liu YL
Gynecol Oncol; 2023 Jul; 174():34-41. PubMed ID: 37149903
[TBL] [Abstract] [Full Text] [Related]
7. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
[TBL] [Abstract] [Full Text] [Related]
8. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
[TBL] [Abstract] [Full Text] [Related]
9. The clinical features and management of Lynch syndrome-associated ovarian cancer.
Ran X; Jing H; Li Z
J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
[TBL] [Abstract] [Full Text] [Related]
10. Pancreatic cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation.
Vietri MT; D'Elia G; Caliendo G; Albanese L; Signoriello G; Napoli C; Molinari AM
Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205366
[TBL] [Abstract] [Full Text] [Related]
11. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract] [Full Text] [Related]
12. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract] [Full Text] [Related]
13. [A Case of Diagnosed Lynch Syndrome in a Patient with Ureteral cancer].
Kobayashi G; Takayanagi A; Shindo T; Hashimoto K; Kobayashi K; Fukuta F; Tanaka T; Masumori N
Hinyokika Kiyo; 2021 Jun; 67(6):229-232. PubMed ID: 34265897
[TBL] [Abstract] [Full Text] [Related]
14. Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
Laish I; Friedman E; Levi-Reznick G; Kedar I; Katz L; Levi Z; Halpern N; Parnasa S; Abu-Shatya A; Half E; Goldberg Y
Breast Cancer Res Treat; 2021 Aug; 188(3):685-694. PubMed ID: 34086170
[TBL] [Abstract] [Full Text] [Related]
15. Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
Seppälä TT; Dominguez-Valentin M; Crosbie EJ; Engel C; Aretz S; Macrae F; Winship I; Capella G; Thomas H; Hovig E; Nielsen M; Sijmons RH; Bertario L; Bonanni B; Tibiletti MG; Cavestro GM; Mints M; Gluck N; Katz L; Heinimann K; Vaccaro CA; Green K; Lalloo F; Hill J; Schmiegel W; Vangala D; Perne C; Strauß HG; Tecklenburg J; Holinski-Feder E; Steinke-Lange V; Mecklin JP; Plazzer JP; Pineda M; Navarro M; Vida JB; Kariv R; Rosner G; Piñero TA; Pavicic W; Kalfayan P; Ten Broeke SW; Jenkins MA; Sunde L; Bernstein I; Burn J; Greenblatt M; de Vos Tot Nederveen Cappel WH; Della Valle A; Lopez-Koestner F; Alvarez K; Büttner R; Görgens H; Morak M; Holzapfel S; Hüneburg R; von Knebel Doeberitz M; Loeffler M; Redler S; Weitz J; Pylvänäinen K; Renkonen-Sinisalo L; Lepistö A; Hopper JL; Win AK; Lindor NM; Gallinger S; Le Marchand L; Newcomb PA; Figueiredo JC; Thibodeau SN; Therkildsen C; Wadt KAW; Mourits MJE; Ketabi Z; Denton OG; Rødland EA; Vasen H; Neffa F; Esperon P; Tjandra D; Möslein G; Rokkones E; Sampson JR; Evans DG; Møller P
Eur J Cancer; 2021 May; 148():124-133. PubMed ID: 33743481
[TBL] [Abstract] [Full Text] [Related]
16. OTUB1 stabilizes mismatch repair protein msh2 by blocking ubiquitination.
Wu Q; Huang Y; Gu L; Chang Z; Li GM
J Biol Chem; 2021; 296():100466. PubMed ID: 33640455
[TBL] [Abstract] [Full Text] [Related]
17. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
18. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The cancer Genome Atlas subgroups.
Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
[TBL] [Abstract] [Full Text] [Related]
19. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Lui GYL; Shaw R; Schaub FX; Stork IN; Gurley KE; Bridgwater C; Diaz RL; Rosati R; Swan HA; Ince TA; Harding TC; Gadi VK; Goff BA; Kemp CJ; Swisher EM; Grandori C
EBioMedicine; 2020 Oct; 60():102988. PubMed ID: 32927276
[TBL] [Abstract] [Full Text] [Related]
20. Diffuse Intratumoral Stromal Inflammation in ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract] [Full Text] [Related]
[Next]
